SEBI Reg. Investment Advisor

Download App

MoneyWorks4Me

Kerala Ayurveda rises on getting nod to enter into BTA for purchase of Nutraceutical product range

13 Jul 2023 Evaluate

Kerala Ayurveda is currently trading at Rs. 110.60, up by 5.05 points or 4.78% from its previous closing of Rs. 105.55 on the BSE.

The scrip opened at Rs. 107.30 and has touched a high and low of Rs. 110.60 and Rs. 106.05 respectively. So far 2045 shares were traded on the counter.

The BSE group 'XT' stock of face value Rs. 10 has touched a 52 week high of Rs. 144.75 on 11-May-2023 and a 52 week low of Rs. 65.60 on 27-Sep-2022.

Last one week high and low of the scrip stood at Rs. 111.45 and Rs. 103.65 respectively. The current market cap of the company is Rs. 111.42 crore.

The promoters holding in the company stood at 61.52%, while Institutions and Non-Institutions held 0.05% and 38.44% respectively.

Kerala Ayurveda (KAL) has received approval for entering into a Business Transfer Agreement (BTA) for purchase of Nutraceutical product range- Nutraveda, one of the Business Undertakings of Katra Phytochem India (KPIPL). The company is already present in the business of manufacturing and selling ayurveda products. The proposed transaction will help the company to expand its presence in the said space through increase in product pipeline. The Board of Directors of the company at its meeting held on July 12, 2023 has approved the same. 

KAL was founded on the banks of river Periyar at Aluva, Kochi, Kerala, India in 1945 by Late Vaidyan K G K Panicker, the renowned Ayurvedacharya. He was a doyen in Ayurvedic system, a visionary and a mentor.


Kerala Ayurveda Share Price

245.35 3.10 (1.28%)
17-Apr-2026 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1675.20
Dr. Reddys Lab 1235.40
Cipla 1238.30
Zydus Lifesciences 942.55
Lupin 2324.25
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through:

×